BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 15179033)

  • 1. Mechanism of transcriptional repression by TEL/RUNX1 fusion protein.
    Lee YJ; Kim JH; Bae S; Rho SK; Choe SY
    Mol Cells; 2004 Apr; 17(2):217-22. PubMed ID: 15179033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins.
    Heibert SW; Lutterbach B; Durst K; Wang L; Linggi B; Wu S; Wood L; Amann J; King D; Hou Y
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S31-4. PubMed ID: 11587363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein.
    Fenrick R; Amann JM; Lutterbach B; Wang L; Westendorf JJ; Downing JR; Hiebert SW
    Mol Cell Biol; 1999 Oct; 19(10):6566-74. PubMed ID: 10490596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between cellular localization of TEL/AML1 fusion protein and repression of AML1-mediated transactivation of CR1 gene.
    Rho JK; Kim JH; Yu J; Choe SY
    Biochem Biophys Res Commun; 2002 Sep; 297(1):91-5. PubMed ID: 12220513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ETO, but not leukemogenic fusion protein AML1/ETO, augments RBP-Jkappa/SHARP-mediated repression of notch target genes.
    Salat D; Liefke R; Wiedenmann J; Borggrefe T; Oswald F
    Mol Cell Biol; 2008 May; 28(10):3502-12. PubMed ID: 18332109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TEL/AML1 shows dominant-negative effects over TEL as well as AML1.
    Gunji H; Waga K; Nakamura F; Maki K; Sasaki K; Nakamura Y; Mitani K
    Biochem Biophys Res Commun; 2004 Sep; 322(2):623-30. PubMed ID: 15325275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recruitment of the nuclear receptor corepressor N-CoR by the TEL moiety of the childhood leukemia-associated TEL-AML1 oncoprotein.
    Guidez F; Petrie K; Ford AM; Lu H; Bennett CA; MacGregor A; Hannemann J; Ito Y; Ghysdael J; Greaves M; Wiedemann LM; Zelent A
    Blood; 2000 Oct; 96(7):2557-61. PubMed ID: 11001911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple subnuclear targeting signals of the leukemia-related AML1/ETO and ETO repressor proteins.
    Barseguian K; Lutterbach B; Hiebert SW; Nickerson J; Lian JB; Stein JL; van Wijnen AJ; Stein GS
    Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15434-9. PubMed ID: 12427969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.
    Wichmann C; Chen L; Heinrich M; Baus D; Pfitzner E; Zörnig M; Ottmann OG; Grez M
    Cancer Res; 2007 Mar; 67(5):2280-9. PubMed ID: 17332359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acetylation inactivates the transcriptional repressor BCL6.
    Bereshchenko OR; Gu W; Dalla-Favera R
    Nat Genet; 2002 Dec; 32(4):606-13. PubMed ID: 12402037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acetylation-mediated transcriptional activation of the ETS protein ER81 by p300, P/CAF, and HER2/Neu.
    Goel A; Janknecht R
    Mol Cell Biol; 2003 Sep; 23(17):6243-54. PubMed ID: 12917345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AML-2 is a potential target for transcriptional regulation by the t(8;21) and t(12;21) fusion proteins in acute leukemia.
    Meyers S; Lenny N; Sun W; Hiebert SW
    Oncogene; 1996 Jul; 13(2):303-12. PubMed ID: 8710369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple regions of ETO cooperate in transcriptional repression.
    Hildebrand D; Tiefenbach J; Heinzel T; Grez M; Maurer AB
    J Biol Chem; 2001 Mar; 276(13):9889-95. PubMed ID: 11150306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The nuclear receptor co-repressor (N-CoR) utilizes repression domains I and III for interaction and co-repression with ETO.
    Lausen J; Cho S; Liu S; Werner MH
    J Biol Chem; 2004 Nov; 279(47):49281-8. PubMed ID: 15377655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular targeting of aberrant transcription factors in leukemia: strategies for RUNX1/ETO.
    Wichmann C; Grez M; Lausen J
    Curr Drug Targets; 2010 Sep; 11(9):1181-91. PubMed ID: 20583973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular basis for a dominant inactivation of RUNX1/AML1 by the leukemogenic inversion 16 chimera.
    Huang G; Shigesada K; Wee HJ; Liu PP; Osato M; Ito Y
    Blood; 2004 Apr; 103(8):3200-7. PubMed ID: 15070703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription.
    Hiebert SW; Sun W; Davis JN; Golub T; Shurtleff S; Buijs A; Downing JR; Grosveld G; Roussell MF; Gilliland DG; Lenny N; Meyers S
    Mol Cell Biol; 1996 Apr; 16(4):1349-55. PubMed ID: 8657108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein.
    Lutterbach B; Sun D; Schuetz J; Hiebert SW
    Mol Cell Biol; 1998 Jun; 18(6):3604-11. PubMed ID: 9584201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TEL-AML1 preleukemic activity requires the DNA binding domain of AML1 and the dimerization and corepressor binding domains of TEL.
    Morrow M; Samanta A; Kioussis D; Brady HJ; Williams O
    Oncogene; 2007 Jun; 26(30):4404-14. PubMed ID: 17237815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The leukemia-associated gene TEL encodes a transcription repressor which associates with SMRT and mSin3A.
    Chakrabarti SR; Nucifora G
    Biochem Biophys Res Commun; 1999 Nov; 264(3):871-7. PubMed ID: 10544023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.